Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

Phase 3

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Magrolimab
Drug: Venetoclax
Drug: Azacitidine
Drug: Placebo

Registration Number: NCT05079230

Lead Sponsor: Gilead Sciences

Brief Summary: The goal of this clinical study is to compare the study drugs, magrolimab + venetoclax + azacitidine, versus placebo + venetoclax + azacitidine in participants with untreated acute myeloid leukemia (AML) who are not able to have chemotherapy.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 378

Inclusion Criteria

Previously untreated individuals with histological confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity. Individuals must be considered ineligible for intensive chemotherapy, defined by the following:
- ≥ 75 years of age; Or
- ≥ 18 to 74 years of age with at least 1 of the following comorbidities:
  - Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3
  - Diffusing capacity of the lung of carbon monoxide ≤ 65% or forced expiratory volume in 1 second ≤ 65%
  - Left ventricular ejection fraction ≤ 50%
  - Baseline creatinine clearance ≥ 30 mL/min to < 45 mL/min calculated by the Cockcroft Gault formula or measured by 24-hour urine collection
  - Hepatic disorder with total bilirubin > 1.5 x upper limit of normal (ULN)
  - Any other comorbidity that the investigator judges to be incompatible with intensive chemotherapy
- ECOG performance status:
  - Of 0 to 2 for individuals ≥ 75 years of age Or
  - Of 0 to 3 for individuals ≥ 18 to 74 years of age
Individuals with white blood cell (WBC) count ≤ 20 x 10^3/μL prior to randomization. If the individual's WBC is > 20 x10^3/μL prior to randomization, the individual can be enrolled, assuming all other eligibility criteria are met. However, the WBC should be ≤ 20 x 10^3/μL prior to the first dose of study treatment and prior to each magrolimab/placebo dose during Cycle 1.
- Note: Individuals can be treated with hydroxyurea and/or leukapheresis prior to randomization and throughout the study to reduce the WBC to ≤ 20 x 10^3/μL to enable eligibility for study drug dosing
Hemoglobin must be ≥ 9 g/dL prior to initial dose of study treatment
- Note: Transfusions are allowed to meet hemoglobin eligibility
Pretreatment blood cross-match completed

Key

Exclusion Criteria

Prior treatment with any of the following:
- cluster of differentiation 47 (CD47) or signal regulatory protein alpha (SIRPα)-targeting agents
- Antileukemic therapy for the treatment of AML (eg, hypomethylating agents (HMAs), low-dose cytarabine, and/or venetoclax), excluding hydroxyurea
  - Note: Individuals with prior MDS who have not received prior HMAs or venetoclax or chemotherapeutic agents for MDS may be enrolled in the study. Prior treatment with myelodysplastic syndrome (MDS) therapies including, but not limited to lenalidomide, erythroid-stimulating agents, or similar red blood cell negative (RBC-), white blood cell negative (WBC-), or platelet-direct therapies or growth factors is allowed for these individuals.
Clinical suspicion of or documented active central nervous system (CNS) involvement with AML
Individuals who have acute promyelocytic leukemia
Second malignancy, except MDS, treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which individuals are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Magrolimab + Venetoclax + Azacitidine	Magrolimab	Participants will receive * magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.
Magrolimab + Venetoclax + Azacitidine	Venetoclax	Participants will receive * magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.
Magrolimab + Venetoclax + Azacitidine	Azacitidine	Participants will receive * magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.
Magrolimab Matching Placebo + Venetoclax + Azacitidine	Venetoclax	Participants will receive * magrolimab matching placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.
Magrolimab Matching Placebo + Venetoclax + Azacitidine	Azacitidine	Participants will receive * magrolimab matching placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.
Magrolimab Matching Placebo + Venetoclax + Azacitidine	Placebo	Participants will receive * magrolimab matching placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter * venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter * azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle Each cycle is 28 days.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	Up to 1.6 years	OS was measured from the date of randomization to the date of death from any cause. Participants were censored at last known alive date. Kaplan-Meier (KM) estimates were used in outcome measure analysis.

Secondary Outcome Measures

Name	Time	Method
Rate of Complete Remission (CR)	Up to 1.6 years	CR was defined as the percentage of the participants who achieved CR (including CRMRD- and CRMRD+/unk) within 6 cycles of treatment as determined by the investigator while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT) within the response assessment window of 1.6 years. Definitions for CRMRD- and CRMRD+/unk were mentioned in outcome measure #2. Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis. Each cycle was of 28 days.
Rate of Complete Remission (CR) + Complete Remission With Partial Hematologic Recovery (CRh)	Up to 1.6 years	The CR + CRh rate was defined as the percentage of participants who achieved a CR (including CR without minimal residual disease (CRMRD-) and CR with positive or unknown MRD (CRMRD+/unk)) or CRh as defined by CR with partial platelet and absolute neutrophil count recovery within 6 cycles of treatment while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT). CRMRD- and CRMRD+/unk: neutrophils \>1.0 ×10\^9/L, platelets \>100 ×10\^9/L, \<5% bone marrow blasts, no circulating blasts or extramedullary disease (confirmed by flow cytometry \<0.1% sensitivity for CRMRD-) within the response assessment window of 1.6 years. Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis. Each cycle was of 28 days.
Event-Free Survival (EFS)	Up to 1.6 years	EFS was defined as time from the date of randomization to the earliest date of the documented relapse from CR, treatment failure (defined as failure to achieve CR within 6 cycles of treatment), or death from any cause within the response window. KM estimates were used in outcome measure analysis. CR is defined in outcome measure 2.
Duration of CR + CRh in Participants Who Achieved Complete Remission (CR) or Complete Remission With Partial Hematologic Recovery (CRh)	Up to 1.6 years	The duration of CR + CRh was measured from the time the assessment criteria were first met for CR (including CRMRD- and CRMRD+/unk) or CRh within 6 cycles of treatment until the first date of AML relapse or death (including assessments post SCT). Those who were not observed to have relapsed disease or death while on study were censored at the date of their last response assessment with no evidence of relapse on or prior to the data cut off date within the response assessment window of 1.6 years. Participants started taking new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse, duration of CR + CRh were censored at the last response assessment before the initiation of the new anti-AML therapies. CR and CRh are defined in Outcome Measure #2. Each cycle was of 28 days.
Duration of Complete Remission (DCR) in Participants Who Achieved Complete Remission (CR)	Up to 1.6 years	The DCR was measured from the time the assessment criteria were first met for CR (including CRMRD- and CRMRD+/unk) within 6 cycles of treatment until the first date of AML relapse or death (including assessments post SCT). Those who were not observed to have relapsed disease or death while on study were censored at the date of their last response assessment with no evidence of relapse on or prior to the data cutoff date within the response assessment window of 1.6 years. Participants started taking new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse, DCR were censored at the last response assessment before the initiation of the new anti-AML therapies. KM estimates were used in outcome measure analysis. CRMRD- and CRMRD+/unk are defined in outcome measure #2. Each cycle was of 28 days.
Red Blood Cell (RBC) Transfusion Independence Conversion Rate	Up to 1.6 years	The RBC transfusion independence conversion rate was the percentage of participants who had a 56-day or longer period with no RBC or whole blood transfusions at any time between the date of the first dose of study treatment and discontinuation of study treatment among all participants who were RBC transfusion dependent at baseline. Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	First dose date up to 1.4 years plus 70 days	An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 70 days after the study drug last dose date or the day before initiation of new anti-AML therapy including stem cell transplantation, whichever is earlier. Percentages were rounded-off.
Percentage of Participants With Anti-Magrolimab Antibodies	Up to 1.6 years	Percentages were rounded off.
Maximum Levels of Serum Anti-Magrolimab Antibodies	Up to 1.6 years
Rate of CR/CRh Without Minimal Residual Disease (CR/CRhMRD-)	Up to 1.6 years	The CR/CRhMRD- rate was the percentage of participants who achieved a CRMRD- or CRhMRD- within 6 cycles of treatment while on study prior to initiation of any new anti-AML therapy or SCT within the response assessment window of 1.6 years. Each cycle was of 28 days. KM estimates were used for outcome measure analysis. CRhMRD- : neutrophils \> 0.5 x 10\^9/L; platelets \> 50 x 10\^9/L; bone marrow blasts \< 5%; MRD negative (determined using multiparameter flow cytometry with a sensitivity of \< 0.1%). Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. Percentages were rounded off.
Rate of CR Without Minimal Residual Disease (CRMRD-)	Up to 1.6 years	The CRMRD- rate was the percentage of participants who achieved a CRMRD- within 6 cycles of treatment SCT within the response assessment window of 1.6 years. Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis. CRMRD is defined in outcome measure #2. Each cycle was of 28 days. Percentages were rounded off
Platelet Transfusion Independence Conversion Rate	Up to 1.6 years	The platelet transfusion independence conversion rate was the percentage of participants who had a 56-day or longer period with no platelet transfusions at any time between the date of the first dose of study treatment and discontinuation of study treatment among all participants who were platelet transfusion dependent at baseline. Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis.
Time to First Deterioration (TTD) on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale	Up to 1.6 years	The TTD on the EORTC QLQ-C30 GHS/QoL scale was defined as time from the date of randomization to the time a participant experienced at least 1 threshold value deterioration from baseline or death, whichever was earlier. Questionnaire includes 30 questions resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 GHS/QoL scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). After linear transformation, all scales and single item measures range in score from 0-100. Higher score on GHS/QoL scale meant better GHS/QoL. KM estimates were used in outcome measure analysis.
Time to First Deterioration (TTD) on the EORTC QLQ-C30 Physical Functioning Scale	Up to 1.6 years	The TTD on the EORTC QLQ-C30 physical functioning scale was defined as time from the date of randomization to the time a participant experienced at least 1 threshold value deterioration from baseline or death, whichever is earlier. Physical functioning scale is one of the five functional scales of the EORTC QLQ C30 questionnaire. After linear transformation, scale range in score from 0-100. A higher score on functional scales means better functioning and better quality of life. KM estimates were used in outcome measure analysis.
Percentage of Participants Experiencing Grade 3 or Higher Treatment-Emergent Laboratory Abnormalities	First dose date up to 1.4 years, plus 70 days	Treatment-emergent laboratory abnormalities were defined as values that increased by at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 70 days or the day before the initiation of new anti-AML therapy including SCT, whichever came first, and were summarized by treatment group. Severity grades were defined by the CTCAE Version 5.0. 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Life-Threatening; 5 = Death. Percentages were rounded-off.
Serum Concentration of Magrolimab Over Time	Predose on Day 1, Day 8, Day 15, Day 29; Predose on Day 57 and 1 hour post-dose; Predose on Day 113, Day 169, Day 253, and Day 337.

Trial Locations

Locations (164): Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
UC Irvine Health- Chao Family Comprehensive Cancer Center
🇺🇸
Orange, California, United States
The University of Iowa Hospitals and Clinics
🇺🇸
Iowa City, Iowa, United States
SSM Health Saint Louis University Hospital
🇺🇸
Saint Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey
🇺🇸
New Brunswick, New Jersey, United States
Novant Health Cancer Institute Hematology- Charlotte
🇺🇸
Charlotte, North Carolina, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
🇺🇸
Duarte, California, United States
Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital
🇺🇸
New York, New York, United States
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸
Hackensack, New Jersey, United States
University of Arkansas for Medical Sciences
🇺🇸
Little Rock, Arkansas, United States
Community Cancer Institute
🇺🇸
Fresno, California, United States
Baptist MD Anderson Cancer Center
🇺🇸
Jacksonville, Florida, United States
Hanusch Krankenhaus
🇦🇹
Vienna, Austria
Rabin Medical Center
🇮🇱
Petah Tikva, Israel
IRCCS Istituto Clinico Humanitas
🇮🇹
Milano, Italy
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Severance Hospital
🇰🇷
Seoul, Korea, Republic of
Canberra Hospital
🇦🇺
Woden, Australian Capital Territory, Australia
Hospital General Universitario Gregorio Maranon
🇪🇸
Madrid, Spain
Asan Medical Center
🇰🇷
Seoul, Korea, Republic of
Kaohsiung Chang Gung Memorial Hospital
🇨🇳
Kaohsiung, Taiwan
Szpital Wojewodozki w Opolu Sp. z 0.0. Oddzial Klinixzny Hematologii, Onkologii Hematologicznej i Chorob Wemnetrznych
🇵🇱
Opole, Poland
Hospital Universitari I Politecnic La Fe
🇪🇸
Valencia, Spain
Hadassah University Hospital Ein Kerem
🇮🇱
Jerusalem, Israel
The Chaim Sheba Medical Center
🇮🇱
Ramat Gan, Israel
Shaare Zedek Medical Center
🇮🇱
Jerusalem, Israel
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M.Kopernika w Lodzi, Oddzial Hematologii Ogolnej
🇵🇱
Łódź, Poland
Meander Medisch Centrum
🇳🇱
Amersfoort, Netherlands
Azienda Ospedaliero Universitaria delle Marche - SOD Clinica di Ematologia
🇮🇹
Ancona, Italy
Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi
🇮🇹
Bologna, Italy
ASST Monza-Ospedale San Gerardo
🇮🇹
Monza, Italy
Oslo University Hospital, Department of Hematology
🇳🇴
Oslo, Norway
King's College Hospital
🇬🇧
London, United Kingdom
Clatterbridge Cancer Centre NHS Foundation Trust
🇬🇧
Liverpool, United Kingdom
Complejo Asistencial Universitario de Salamanca - Hospital Clinico
🇪🇸
Salamanca, Spain
The Catholic University of Korea Seoul Saint Mary's Hospital
🇰🇷
Seoul, Korea, Republic of
Azienda Ospedaliera di Perugia - Santa Maria della Misericordia
🇮🇹
Perugia, Italy
Hospital Universitario Araba
🇪🇸
Alava, Spain
Newcastle upon Tyne Hospitals Foundation Trust
🇬🇧
Newcastle upon Tyne, United Kingdom
Hospital Universitario Reina Sofia
🇪🇸
Cordoba, Spain
Hospital Universitario Ramon y Cajal
🇪🇸
Madrid, Spain
Inselspital Universitätsspital Bern
🇨🇭
Berne, Switzerland
China Medical University Hospital
🇨🇳
Taichung, Taiwan
Universitair Medisch Centrum Groningen
🇳🇱
Groningen, Netherlands
Hospital Universitario 12 de Octubre
🇪🇸
Madrid, Spain
Hospital Universitario La Paz
🇪🇸
Madrid, Spain
The Christie NHS Foundation Trust
🇬🇧
Manchester, United Kingdom
Complejo Hospitalario Universitario de Santiago de Compostela
🇪🇸
Santiago de Compostela, Spain
Hospital Universitario Quironsalud Madrid
🇪🇸
Madrid, Spain
Leeds Teaching Hospitals NHS Trust
🇬🇧
Leeds, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
🇬🇧
Oxford, United Kingdom
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
West Penn Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
🇺🇸
Baltimore, Maryland, United States
Amphia Hospital, department Oncologie, Route 43
🇳🇱
Breda, Netherlands
HagaZiekenhuis
🇳🇱
Den Haag, Netherlands
Medisch Spectrum Twente - Enschede Koningsplein
🇳🇱
Enschede, Netherlands
Medisch Centrum Leeuwarden
🇳🇱
Leeuwarden, Netherlands
Erasmus Medisch Centrum
🇳🇱
Rotterdam, Netherlands
Indiana Blood and Marrow Transplantation - Clinic
🇺🇸
Indianapolis, Indiana, United States
Houston Methodist Hospital Cancer Center
🇺🇸
Houston, Texas, United States
MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Virginia Mason Franciscan Health
🇺🇸
Seattle, Washington, United States
Fred Hutchinson Cancer Center
🇺🇸
Seattle, Washington, United States
University Hospital Gent
🇧🇪
Gent, Belgium
University of Rochester Medical Center
🇺🇸
Rochester, New York, United States
OU Health Stephenson Cancer Center
🇺🇸
Oklahoma City, Oklahoma, United States
Intermountain Health - LDS Hospital
🇺🇸
Salt Lake City, Utah, United States
Centre Hospitalier Lyon-Sud (CHLS)
🇫🇷
Pierre-Bénite, France
Barts Health NHS Trust
🇬🇧
London, United Kingdom
Marien Hospital Dusseldorf GmbH, Klinik Fur Onkologie, Hamatologie Und Palliativmedizin
🇩🇪
Düsseldorf, Germany
Debreceni Egyetem Klinikai Központ Belgyogyaszati Klinika B epulet Hematologia
🇭🇺
Hajdu-bihar, Hungary
Parkview Research Center
🇺🇸
Fort Wayne, Indiana, United States
Loyola University Medical Center
🇺🇸
Maywood, Illinois, United States
University of Massachusetts Worcester
🇺🇸
Worcester, Massachusetts, United States
New York-Presbyterian/Weill Cornell Medical Center
🇺🇸
New York, New York, United States
University Hospitals Cleveland Medical Center
🇺🇸
Cleveland, Ohio, United States
Baylor University Medical Center
🇺🇸
Dallas, Texas, United States
Brooke Army Medical Center
🇺🇸
Fort Sam Houston, Texas, United States
Border Medical Oncology Research Unit
🇦🇺
Albury, New South Wales, Australia
Concord Repatriation General Hospital
🇦🇺
Concord, New South Wales, Australia
Liverpool Hospital
🇦🇺
Liverpool, New South Wales, Australia
St George Hospital, Clinical Research Unit Haemotology, Division of Cancer Services
🇦🇺
Sydney, New South Wales, Australia
Gold Coast University Hospital
🇦🇺
Southport, Queensland, Australia
Ziekenhuis Netwerk Antwerp (ZNA) - Stuivenberg
🇧🇪
Antwerp, Belgium
Peter MacCallum Cancer Centre
🇦🇺
Melbourne, Victoria, Australia
Northern Health
🇦🇺
Epping, Victoria, Australia
Monash University, Eastern Health-Box Hill Hospital
🇦🇺
Box Hill, Victoria, Australia
Centre Integre Universitaire de Sante et de Services Sociaux(CIUSSS) de l'Est-de-L'Ile-de- Montreal - Hopital Maisonneuve-Rosemont
🇨🇦
Montreal, Canada
Queen Elizabeth II (QEII) Health Sciences Centre
🇨🇦
Halifax, Canada
Princess Margaret Cancer Centre - University Health Network
🇨🇦
Toronto, Canada
CancerCare Manitoba
🇨🇦
Winnipeg, Canada
Fakultni nemocnice Ostrava, Klinika hematoonkologie
🇨🇿
Ostrava, Czechia
Fakultni nemocine Olomouc, Hemato-onkologicka klinika
🇨🇿
Olomouc, Czechia
Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika FN Brno a LF MU
🇨🇿
Jihormoravsky KRAJ, Czechia
CHU d'Angers
🇫🇷
Angers, France
Fakulti nemocnice Kralovske Vinohrady, Internf hematologicka klinika FNKV a 3. LF UK
🇨🇿
Prague, Czechia
Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika, Hematologicka ambulance
🇨🇿
Praha 2, Czechia
Hopital Avicenne
🇫🇷
Bobigny, France
CHU Amiens Picardie
🇫🇷
Amiens Cedex 1, France
Hopitaux Universitaires Henri Mondor
🇫🇷
Creteil, France
Centre Hospitalier de Versailles
🇫🇷
Le Chesnay Cedex, France
Centre Hospitalier Universitaire Grenoble Alpes
🇫🇷
La Tronche, France
Hôpital Claude Huriez (CHRU de Lillle)
🇫🇷
Lille Cedex, France
Hopital Saint-Louis
🇫🇷
Paris, France
Centre Leon Berard
🇫🇷
Lyon Cedex 08, France
Centre Hospitalier Universitaire Nantes - Hotel Dieu
🇫🇷
Nantes, France
Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
🇫🇷
Toulouse, France
CHU de Nancy - Hopitaux de Brabois
🇫🇷
Vandoeuvre-les-Nancy, France
Institut de Cancérologie Strasbourg Europe (ICANS)
🇫🇷
Strasbourg, France
Universitatsklinikum Dusseldorf, Klink fur Hamatologie, Onkologie und Klinische Immunologie
🇩🇪
Dusseldorf, Germany
Universitätsklinikum Bonn
🇩🇪
Bonn, Germany
Charite - Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie
🇩🇪
Berlin, Germany
Städtisches Klinikum Braunschweig GmbH Medizinische Klinik III/Hämatologie und Onkologie
🇩🇪
Braunschweig, Germany
Asklepios Klink St.Georg
🇩🇪
Hamburg, Germany
Medizinische Hochschule Hannover, Hamatologie, Hamostaseologie, Onkologie und Stammzelltrandsplantation
🇩🇪
Hannover, Germany
Malteser Krankenhaus St. Franziskus Hospital,Med.Klinik I
🇩🇪
Flensburg, Germany
Universitatsklinikum Frankfurt Goethe Universitat Med. Klink II
🇩🇪
Frankfurt, Germany
Universitätsklinikum Magdeburg
🇩🇪
Magdeburg, Germany
Johannes Wesling Klinikum Minden Universitätsklinik fur Hämatologie, Onkologie, Hämostaseologie und Pastativrndezin, Universitatsklinik der Ruhr-Unive
🇩🇪
Minden, Germany
Klinikum rechts der Isar Technischen Universitat Munchen
🇩🇪
Muenchen, Germany
Universitatsklinikum Regensburg, Klink fur Innere Medizin III
🇩🇪
Regensburg, Germany
Klinikum Oldenburg, Rahel-Straus-Straße 10
🇩🇪
Oldenburg, Germany
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital
🇭🇰
Hong Kong, Hong Kong
Universitatsklinikum Ulm, Zentrum fur Innere Medizin, Klinik fur Innere Medizin III
🇩🇪
Ulm, Germany
Queen Mary Hospital
🇭🇰
Hong Kong, Hong Kong
Tuen Mun Hospital
🇭🇰
Hong Kong, Hong Kong
Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika
🇭🇺
Budapest, Hungary
Petz Aladár Egyetemi Oktató Kórház II. Belgyógyaszat - Haematológia
🇭🇺
Gyor, Hungary
Rambam Health Care Campus
🇮🇱
Haifa, Israel
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Kozpont
🇭🇺
Szeged, Hungary
ASST Papa Giovanni XXIII
🇮🇹
Bergamo, Italy
Azienda Sanitaria Territoriale Pesaro e Urbino - "Stabilimento Ospedaliero San Salvatore - Muraglia" - U.O. Ematologia e Centro Trapianti
🇮🇹
Pesaro, Italy
St. Antonius Ziekenhuis, Nieuwegein
🇳🇱
Nieuwegein, Netherlands
Masstricht Universitair Medisch Centrum
🇳🇱
Maastricht, Netherlands
Jeroen Bosch Ziekenhuis
🇳🇱
's-Hertogenbosch, Netherlands
Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Oddzial Hematologiczny
🇵🇱
Lublin, Poland
Amsterdam Universitair Medische Centra-Locatie Vrije Universiteit Medisch Centrum
🇳🇱
Amsterdam, Netherlands
Canisius Wilhelmina Ziekenhuis
🇳🇱
Nijmegen, Netherlands
Hospital Regional Universitario de Malaga
🇪🇸
Malaga, Spain
University Hospitals Bristol and Weston NHS Foundation Trust
🇬🇧
Bristol, United Kingdom
National Cheng Kung University Hospital
🇨🇳
Taipei, Taiwan
The Royal Wolverhampton NHS Trust
🇬🇧
Wolverhampton, United Kingdom
South Warwickshire University NHS Foundation Trust
🇬🇧
Warwick, United Kingdom
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Novant Health Cancer Institute Hematology - Forsyth
🇺🇸
Winston-Salem, North Carolina, United States
Wake Forest Baptist Health
🇺🇸
Winston-Salem, North Carolina, United States
Providence Cancer Institute Franz Clinic
🇺🇸
Portland, Oregon, United States
Froedtert Hospital and the Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Wiener Gesundheitsverbund, Klinik Hietzing
🇦🇹
Wien, Austria
Penn State Hershey Medical Center
🇺🇸
Hershey, Pennsylvania, United States
Ordensklinikum Linz GmbH Elisabethinen
🇦🇹
Linz, Austria
National Taiwan University Hospital
🇨🇳
Taipei, Taiwan
University Hospital Leuven (UZ Leuven) - Campus Gasthuisberg
🇧🇪
Leuven, Belgium
Centre Hospitalier Universitaire de Liege
🇧🇪
Liege, Belgium
Hopital de Jolimont
🇧🇪
Haine-Saint-Paul, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪
Brussels, Belgium
MidAmerica Division, Inc., c/o Research Medical Center
🇺🇸
Kansas City, Missouri, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
Hospital Clinic de Barcelona
🇪🇸
Barcelona, Spain
Blackpool Teaching Hospitals NHS Foundation Trust
🇬🇧
Blackpool, United Kingdom
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States
Princess Margaret Hospital
🇭🇰
Hong Kong, Hong Kong